Myriad Genetics, Inc. (NASDAQ:MYGN)
| CAPS Rating |
|
|---|---|
| Open | $23.22 |
| Previous Close | $23.37 |
| Daily Range | $22.97 - $23.35 |
| 52-Week Range | $17.51 - $25.89 |
| Market Cap | $1.98B |
| P/E Ratio | 18.40 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 406,874 |
| Average Daily Volume | 0 |
MYGN
VS S&P 500 (SPY)
How do you think MYGN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MYGN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MYGN News and Commentary
- Myriad Genetics Outruns Estimates Again – The Motley Fool
- Qiagen Posts a Solid 4Q - Analyst Blog – NASDAQ
- Myriad Beats, Raises Guidance - Analyst Blog – NASDAQ
- Cepheid Tops Estimates - Analyst Blog – NASDAQ
- Genomic's Useful Colon Cancer Test - Analyst Blog – NASDAQ
- Myriad Gets Rights to RAD51C Gene - Analyst Blog – NASDAQ
- Qiagen Enhances Presence in Japan - Analyst Blog – NASDAQ
- Amass a Fortune With These Stocks – The Motley Fool
- Genomic Looks to Diversify Offering (revised) - Analyst Blog – NASDAQ
- Genomic Looks to Diversify Offering - Analyst Blog – NASDAQ
- Qiagen Expands QIAensemble Portfolio - Analyst Blog – NASDAQ
- Another Entry in the Genome Patent Rumble – The Motley Fool
- Myriad Genetics Passes This Key Test – The Motley Fool
- Myriad Reverts to Neutral - Analyst Blog – NASDAQ
- 5-Star ETFs Poised to Pop: SPDR S&P Biotech – The Motley Fool
- Myriad Bracanalysis Proves Cheaper - Analyst Blog – NASDAQ
- Genomic DCIS Score Coming Shortly - Analyst Blog – NASDAQ
- Supreme Court Grapples With Patents On Diagnostic Tests – SmartMoney
- Myriad Genetics Shares Popped: What You Need to Know – The Motley Fool
- Afternoon Roundup: Today's Top Stories – The Motley Fool
RSS Headlines
Fool UK
